Sales of multiple sclerosis drug Tecfidera helped treat this pharmaceutical firm to a hale 2014 (though recent results missed targets).
Company Information
Location | Cambridge, MA |
Industry | Pharmaceuticals |
Sector | Health Care |
Fortune 500 Rank | 298 |
Fortune 500 Profile | http://fortune.com/fortune500/biogen-298/ |
Current Streak | 1 |
Years on List | 1 |
CEO | George A. Scangos |
Website | http://www.biogen.com |
Revenue, Net Income
Revenue Past Four Quarters | 10,129 |
Net Income Past Four Quarters | 3,277 |
Growth Rates
EPS 3 yr Annual Growth Rate | 35% |
Rev 3 yr Annual Growth Rate | 26% |
Total Return 3 yr Annual Rate | 41% |
Beat S&P 3 yr Total Return? | yes |
Rank
EPS Growth Rank | 69 |
Revenue Growth Rank | 63 |
Total Return Rank | 53 |